Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a8/e9/5f/a8e95f8b-aa1d-fc10-a97d-970ed536395a/mza_6256469873985417328.jpg/600x600bb.jpg

Community Health Media

8 episodes

3 days ago

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Medicine

Health & Fitness

RSS

All content for Community Health Media is the property of Community Health Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/42498441/42498441-1757063417492-264e15cb224d9.jpg

Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments

Community Health Media

30 minutes 35 seconds

4 months ago

Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments

In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases. From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 classifications, have moved on from binary to a continuum from low to even ultra-low expression and are reshaping therapeutic paradigms and patient care decisions. Key insights into managing brain metastases, T-DXd associated pneumonitis, optimizing treatment sequencing, and effectively communicating complex medical data to patients highlight the conversation. This episode is essential listening for oncologists, researchers, and advocates interested in the latest shifts in breast cancer therapy.

Topics Covered:

• Historical evolution of HER2 classifications

• Clinical impact of HER2 low and ultra-low categorizations

• DESTINY-Breast trials and groundbreaking T-DXd data

• Management strategies for brain metastases, T-DXd associated pneumonitis

• Patient-centered communication and shared decision-making

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#HER2 #TDXd #MetastaticBreastCancer #BreastCancerResearch #OncologyEducation #CHMConversations #DESTINYBreast04 #FirstLineTherapy #CancerCare

–

Thanks for listening!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media